Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease

NCT03772665 is registered in ClinicalTrials.gov with Kubota Vision Inc. as lead sponsor.

NCT NCT03772665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03772665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease
Lead sponsor
Kubota Vision Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 7, 2019
Completion date
June 23, 2022
Enrollment
194 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt disease